Exact Mass: 532.1983

Nomilinic acid

3-(acetyloxy)-3-[11-(furan-3-yl)-5-(2-hydroxypropan-2-yl)-2,6,10-trimethyl-3,13-dioxo-12,15-dioxatetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan-6-yl]propanoic acid

Nomilinic acid is found in citrus. Nomilinic acid is a constituent of grapefruit seeds

Austalide E

18-Hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-2-yl acetic acid

Austalide E is a metabolite of Aspergillus ustus. Metabolite of Aspergillus ustus.

Austalide D

2-Hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-18-yl acetic acid

Austalide D is a metabolite of Aspergillus ustu Metabolite of Aspergillus ustus.

Ponatinib

3-(2-(imidazo(1,2-b)Pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

Ponatinib is a Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012 (DB08901). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents

Dehydroandrographolide succinate

4-[(1-{[(3-carboxypropanoyl)oxy]methyl}-1,4a-dimethyl-6-methylidene-5-[2-(2-oxo-2,5-dihydrofuran-3-yl)ethenyl]-decahydronaphthalen-2-yl)oxy]-4-oxobutanoic acid

3-[3-[4-[5-(2-Carboxyethyl)-2-hydroxyphenyl]-1,4-bis(carboxymethylamino)butyl]-4-hydroxyphenyl]propanoic acid

3-(3-{4-[5-(2-carboxyethyl)-2-hydroxyphenyl]-1,4-bis[(carboxymethyl)amino]butyl}-4-hydroxyphenyl)propanoic acid

C26H32N2O10 (532.2057)

Plevitrexed

2-{[(2-fluoro-4-{[(4-hydroxy-2,7-dimethylquinazolin-6-yl)methyl](prop-2-yn-1-yl)amino}phenyl)(hydroxy)methylidene]amino}-4-(2H-1,2,3,4-tetrazol-5-yl)butanoate

C26H25FN8O4 (532.1983)

Dehydroandrographolidesuccinate

Kurramine

O-Demethyl-1,2-dehydroapateline

(+)-Maculalactone K

C34H28O6 (532.1886)

Kadcoccilactone J

(+)-Kadcoccilactone J

Rzedowskin A

5,7-bis(Acetyloxy)octahydro-9,10-dihydroxy-2,2,5a,9-tetramethyl-2H-3,9a-methano-1-benzoxepin-6-yl ester 3-phenyloxiranecarboxylic acid

eucalmainoside E

C24H36O13 (532.2156)

CHEMBL4439167

C30H28O9 (532.1733)

(1alpha,2alpha,8beta,9beta)-2,8,14-tris(acetyloxy)-9-(benzoyloxy)-1-hydroxydihydro-beta-agarofuran|rel-5a-[(acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,7-tetrol 4,7-diacetate 5-benzoate

(1alpha,2alpha,8beta,9beta)-2,8,14-tris(acetyloxy)-9-(benzoyloxy)-1-hydroxydihydro-beta-agarofuran|rel-5a-[(acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,7-tetrol 4,7-diacetate 5-benzoate

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanamido]butanedioic acid

C24H32N6O8 (532.2282)

Asn Asp Glu Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-carboxypropanamido]-4-carboxybutanamido]-5-carbamimidamidopentanoic acid

C19H32N8O10 (532.2241)

Asp His Phe Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]butanedioic acid

C23H28N6O9 (532.1918)

1-O-Deacetyl-2α-hydroxykhayanolide E

methyl (2S)-2-[(1S,2S,3S,4R,7S,8S,12R,14R,16R,17R,18S)-8-(furan-3-yl)-1,3,14-trihydroxy-7,16,18-trimethyl-10,15-dioxo-9,13-dioxahexacyclo[14.2.1.02,14.03,12.04,18.07,12]nonadecan-17-yl]-2-hydroxyacetate

Ponatinib (AP24534)

(4S)-4-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-4-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}butanoic acid

C24H32N6O8 (532.2282)

Thr His Phe Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]pentanedioic acid

C24H32N6O8 (532.2282)

C26H25FN8O4 (532.1983)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2021 - Thymidylate Synthase Inhibitor D000970 - Antineoplastic Agents

Hexadecamethylheptasiloxane

C16H48O6Si7 (532.1836)

Bis-PEG5-NHS ester

C22H32N2O13 (532.1904)

Tris(2,4,6-trimethoxyphenyl)phosphine

C27H33O9P (532.1862)

BENZOIC ACID, 4-[4-[(3R)-3-[[[2-OXO-2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]ETHYL]AMINO]CARBONYL]-1-PYRROLIDINYL]-1-PIPERIDINYL]-, METHYL ESTER

C27H31F3N4O4 (532.2297)

Rubrene

C42H28 (532.2191)

BAPTA-tetramethyl Ester

C26H32N2O10 (532.2057)

Oprozomib

Oprozomib (ONX 0912)

C25H32N4O7S (532.1992)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2160 - Proteasome Inhibitor C471 - Enzyme Inhibitor

Bis(tert-butoxy)bis(1-methoxy-2-methyl-2-propoxy)hafnium(IV)

C18H40O6Hf (532.229)

4,6-bis(3-(2-ethylhexyl)thien-2-yl)thieno[3,4-c][1,2,5]thiadiazole

C28H40N2S4 (532.2074)

RHODIUM(III) 2-ETHYLHEXANOATE

C24H45O6Rh (532.2271)

Onvansertib

C24H27F3N8O3 (532.2158)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C177899 - PLK1 Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

Benzamide, 4-methyl-N-(4-((4-methyl-1-piperazinyl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(1,2,4-triazolo(4,3-a)pyridin-3-yl)ethynyl)-

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

Plevitrexed, (+/-)-

C26H25FN8O4 (532.1983)

Ponatinib

Ponatinib (AP24534)

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163790 - Flt-3-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159438 - RET Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents

4-[[2-(3-carboxypropanoyloxy)-1,4a-dimethyl-6-methylidene-5-[(E)-2-(5-oxo-2H-furan-4-yl)ethenyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-4-oxobutanoic acid

longipedumin A

ST 28:7;O5;S

C28H36O8S (532.2131)

IPN60090

C24H27F3N8O3 (532.2158)

IPN-60090 is an orally active and highly selective inhibitor of glutaminase 1?(GLS1; IC50=31 nM), with no activity observed against GLS-2. IPN-60090 exhibits excellent physicochemical and pharmacokinetic properties in vivo. IPN-60090 can be used for solid tumors research, such as lung and ovarian cancers[1][2].

5,7-dihydroxy-8-(3-hydroxy-3-methylbutyl)-2-(4-methoxyphenyl)-3-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}chromen-4-one

(2s,3r,4s,5s,6r)-2-{[4-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-6,7-dimethoxy-3-methylnaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(8r,9r,10r)-5-hydroxy-3,4,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2e)-3-phenylprop-2-enoate

nortryptoquivaline a

C28H28N4O7 (532.1958)

3-hydroxy-4,5,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2(7),3,5,13,18-hexaen-11-yl 3-phenylprop-2-enoate

12-hydroxyamoorastatone

{"Ingredient_id": "HBIN000872","Ingredient_name": "12-hydroxyamoorastatone","Alias": "NA","Ingredient_formula": "C28H36O10","Ingredient_Smile": "CC(=O)OC1CC(C23COC(C1(C2CC(C4(C3C(=O)C(C5(C4C(=O)CC5C6=COC=C6)C)O)C)O)C)O)O","Ingredient_weight": "532.6 g/mol","OB_score": "NA","CAS_id": "152013-84-8","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9364","PubChem_id": "101672375","DrugBank_id": "NA"}

methyl 12-[1-(2h-1,3-benzodioxole-5-carbonyloxy)ethyl]-5-methoxy-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,9-tetraene-10-carboxylate

C30H32N2O7 (532.2209)

2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-15-yl acetate

(1r,2r,4s,16r,17s,18r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-18-yl acetate

(1r,2r,4s,16r,17s,18r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-18-yl acetate

(9r,10r,11s)-3-hydroxy-4,5,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2(7),3,5,13,18-hexaen-11-yl (2e)-3-phenylprop-2-enoate

22-methyl-15,29,31-trioxa-7,22-diazaoctacyclo[19.9.3.2¹⁶,¹⁹.1⁴,³⁰.1¹⁰,¹⁴.0³,⁸.0²⁵,³³.0²⁸,³²]heptatriaconta-1(30),2,4(34),7,10,12,14(37),16,18,25,27,32,35-tridecaene-13,27-diol

22-methyl-15,29,31-trioxa-7,22-diazaoctacyclo[19.9.3.2¹⁶,¹⁹.1⁴,³⁰.1¹⁰,¹⁴.0³,⁸.0²⁵,³³.0²⁸,³²]heptatriaconta-1(30),2,4(34),7,10,12,14(37),16,18,25,27,32,35-tridecaene-13,27-diol

(2r,3r,4r,5r,6r)-5-{[(2s,3r,4r,5r,6r)-5-{[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy}-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-(hydroxymethyl)-2-methoxyoxane-3,4-diol

C20H36O16 (532.2003)

(1r,2r,4s,16r,17s,18r,20s)-18-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate

(1r,2r,4s,16r,17s,18r,20s)-18-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6,8(12),13-trien-2-yl acetate

5-(acetyloxy)-12-(furan-2-carbonyloxy)-2,4-dihydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl furan-2-carboxylate

(1r,2r,4s,15s,16s,17r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-15-yl acetate

(1r,2r,4s,15s,16s,17r,20s)-2-hydroxy-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-15-yl acetate

4,5-bis(acetyloxy)-6-[6-(2-methoxy-2-oxoethyl)-1,5,5-trimethyl-4-oxocyclohex-2-en-1-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxirene-3-carboxylic acid

[(3s,4r,5s)-5-{[(2r,3r,4s,5r,6r)-2-(benzyloxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl (2e)-3-phenylprop-2-enoate

15-(furan-3-yl)-3,10,13,20-tetrahydroxy-2,7,14,20-tetramethyl-5-oxo-6,11,18-trioxahexacyclo[10.8.0.0²,¹⁰.0³,⁷.0¹⁴,¹⁹.0¹⁷,¹⁹]icos-8-en-4-yl acetate

6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

(1s,4as,5r,7s,7as)-5-(acetyloxy)-1-{[(2s,3r,4s,5r,6r)-3,4-bis(acetyloxy)-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4a-hydroxy-7-methyl-1h,5h,6h,7ah-cyclopenta[c]pyran-7-yl acetate

C23H32O14 (532.1792)

(1'r,2's,3r,3'r,4s,5'r,10's,11's,14's)-11'-(furan-3-yl)-3'-hydroxy-5'-(2-hydroxypropan-2-yl)-2',10'-dimethyl-6,13'-dioxo-12',15'-dioxaspiro[oxane-3,6'-tetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan]-4-yl acetate

(1'r,2's,3r,3'r,4s,5'r,10's,11's,14's)-11'-(furan-3-yl)-3'-hydroxy-5'-(2-hydroxypropan-2-yl)-2',10'-dimethyl-6,13'-dioxo-12',15'-dioxaspiro[oxane-3,6'-tetracyclo[8.5.0.0¹,¹⁴.0²,⁷]pentadecan]-4-yl acetate

(1s,2r,4r,5r,6s,8r,10s,11s,12r,14r,15r,16r,19s,21r)-6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

(1s,2r,4r,5r,6s,8r,10s,11s,12r,14r,15r,16r,19s,21r)-6-(furan-3-yl)-4,12,16,19-tetrahydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

(2e,4e,6e,8e)-9-[(2s)-2-hydroxy-4-{[(2e,4e,6e)-1-hydroxy-8-methylnona-2,4,6-trien-1-ylidene]amino}-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl]-n-(2-hydroxy-5-oxocyclopent-1-en-1-yl)nona-2,4,6,8-tetraenimidic acid

(1'r,2s,3'r,8'r,12's,13'r,18'e,20'z,24'r,25's)-12'-hydroxy-13',25'-dimethyl-11',17',22'-trioxo-2',10',16',23'-tetraoxaspiro[oxirane-2,26'-tetracyclo[22.2.1.0³,⁸.0⁸,²⁵]heptacosane]-4',18',20'-triene-5'-carboxylic acid

3,4,5-trihydroxy-6-methyloxan-2-yl 6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]phenazine-1-carboxylate

C25H28N2O11 (532.1693)

(1r,2s,4s,6r,7s,8s,10r,11s,13s,15r,19r,22s,24r)-11,13,24-trihydroxy-7,21,21-trimethyl-8-(4-methyl-5-oxo-2h-furan-2-yl)-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one

(1r,2s,4s,6r,7s,8s,10r,11s,13s,15r,19r,22s,24r)-11,13,24-trihydroxy-7,21,21-trimethyl-8-(4-methyl-5-oxo-2h-furan-2-yl)-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one

(8r,9s,10r)-5-hydroxy-3,4,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaen-8-yl (2e)-3-phenylprop-2-enoate

(1r,2s,4s,6r,7s,8s,10r,11s,13s,15r,19r,22s,24r)-11,13,24-trihydroxy-7,21,21-trimethyl-8-[(2s)-4-methyl-5-oxo-2h-furan-2-yl]-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one

(1r,2s,4s,6r,7s,8s,10r,11s,13s,15r,19r,22s,24r)-11,13,24-trihydroxy-7,21,21-trimethyl-8-[(2s)-4-methyl-5-oxo-2h-furan-2-yl]-3,9,16,20-tetraoxaheptacyclo[11.11.0.0²,⁴.0²,¹⁰.0⁶,¹⁰.0¹⁵,¹⁹.0¹⁵,²²]tetracosan-17-one

(1s,4as,5r,7s,7as)-5-(acetyloxy)-1-{[3,4-bis(acetyloxy)-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4a-hydroxy-7-methyl-1h,5h,6h,7ah-cyclopenta[c]pyran-7-yl acetate

C23H32O14 (532.1792)

(1s,2r,4s,5r,6s,7s,8s,9s)-5,8-bis(acetyloxy)-6-[(acetyloxy)methyl]-4-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

(1s,2r,3s)-2-(3,5-dihydroxyphenyl)-1-[(s)-hydroxy(4-hydroxy-3-methoxyphenyl)methyl]-3-(4-hydroxy-3-methoxyphenyl)-2,3-dihydro-1h-indene-4,6-diol

C30H28O9 (532.1733)

methyl 6-(5-hexyl-2-oxo-5h-furan-3-yl)-8-[hydroxy(6-oxo-2,3-dihydropyran-2-yl)methyl]-4-(hydroxymethylidene)-1,3-dioxo-2-oxaspiro[4.4]nonane-6-carboxylate

(1s,2r,3r,4r,7s,10s,12s,13r,14r,15s,17r,19s,20r)-15-(furan-3-yl)-3,10,13,20-tetrahydroxy-2,7,14,20-tetramethyl-5-oxo-6,11,18-trioxahexacyclo[10.8.0.0²,¹⁰.0³,⁷.0¹⁴,¹⁹.0¹⁷,¹⁹]icos-8-en-4-yl acetate

(1s,2r,3r,4r,7s,10s,12s,13r,14r,15s,17r,19s,20r)-15-(furan-3-yl)-3,10,13,20-tetrahydroxy-2,7,14,20-tetramethyl-5-oxo-6,11,18-trioxahexacyclo[10.8.0.0²,¹⁰.0³,⁷.0¹⁴,¹⁹.0¹⁷,¹⁹]icos-8-en-4-yl acetate